The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
the route used in Russian clinical trials. Olfactory pathway provides efficient CNS delivery. Accurate delivery technique is essential — same as Selank: head slightly ba…
the form studied in all published clinical and preclinical research. Russian commercial formulations: 0.1% nasal drops (100 mcg per 0.1 mL drop) for cognitive and nootro…
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
the form studied in all published clinical and preclinical research. Russian commercial formulations: 0.1% nasal drops (100 mcg per 0.1 mL drop) for cognitive and nootropic use; 1% nasal drops (1,000 mcg per 0.1 mL drop) for clinical stroke protocols. The compound in all referenced trials. COA mass spec should confirm ~815 Da.
the route used in Russian clinical trials. Olfactory pathway provides efficient CNS delivery. Accurate delivery technique is essential — same as Selank: head slightly back, gentle sniff, olfactory mucosa target. Standard concentration: 0.1% for nootropic use (100 mcg per drop); 1% for clinical stroke protocols (1,000 mcg per drop). Community users work with 0.1% exclusively.
Semax is the most clinically legitimate compound in the Western research peptide market and the clearest example of how the same molecule can have excellent evidence for one application and thin evidence for the application everyone actually uses it for. The stroke evidence is real. The nootropic evidence is a mechanistic argument plus community consensus. That distinction deserves to be stated plainly.
The central tension resolved: Semax is a stroke drug that biohackers have repurposed as a productivity tool. The stroke evidence involves multiple Russian clinical trials at 9,000-18,000 mcg/day showing improved neurological recovery on validated outcome scales — the kind of evidence that gets drugs approved. The nootropic evidence involves 11 healthy subjects in 1996 at 250-1,000 mcg/day and a compelling mechanistic story that the community has extensively validated by self-experimentation. Both are real. They are not the same quality of evidence. The community's choice to use Semax for nootropic purposes is defensible — the mechanism operates at lower doses, the safety profile is clean, and the community consensus is strong. It is not a choice supported by the same evidence that supports using it for stroke recovery.
The strongest argument for Semax: it is, by a significant margin, the most mechanistically well-characterized and most clinically validated neuropeptide available to the Western research community. The BDNF mechanism is independently replicated. The dopaminergic activation is documented. The anti-inflammatory cytokine modulation has human clinical data. It is on Russia's essential medicines list — the same category as insulin and aspirin by the logic of that designation. The community reports are among the most consistent in this reference. Whatever one believes about the nootropic dose gap, the biological legitimacy of the compound is well-established.
The strongest argument for caution: every clinical trial is Russian and from development institutions. The n=11 1996 study is the cornerstone of the nootropic evidence base. The forms question (standard vs NA-Semax vs NA-Semax Amidate) is unresolved by any comparative study. WADA coverage is uncertain. Sleep disruption at higher doses is real and consequential for the very users who care most about cognitive performance.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
Russia Approved It. The West Has Never Independently Validated It. And It Might Be the Only Anxiolytic That Doesn't Make You Stupid.
Synthetic β-carboline heterocyclic amine with a compelling in vitro dopaminergic neuroprotective profile and zero human clinical trials. Also a MAO-A inhibitor (IC50 = 1 μM) with tyramine-reaction and serotonin-syndrome risk, plus photosensitizer concerns from UV-activated DNA damage potential.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.